Loading people...
Dima Kuzmin is the Co-founder and Managing Partner of 4BIO Capital and an Assistant Professor Adjunct at the Yale School of Medicine, based in London, United Kingdom. He transitioned into venture capital following an academic career that included a doctoral fellowship at the Max Planck Institute for Brain Research and a research fellowship at University College London. Kuzmin holds a PhD in Neurochemistry from Lomonosov Moscow State University and an MSc from the University of Oxford, authoring 12 peer-reviewed publications in journals including Cell and Nature. Since establishing 4BIO Capital in 2014, he has directed early-stage investments across the biotechnology sector, backing companies like RetroSense Therapeutics, which was acquired by Allergan for $550 million in 2016. His current focus centers on funding advanced curative therapies and researching the clinical trial design of gene treatments.
Dima Kuzmin stands as a prominent figure in the biotechnology investment landscape, serving as a Managing Partner at 4BIO Capital. This specialist venture capital firm is renowned for its dedicated focus on advanced therapies, including gene therapy, cell therapy, RNA therapy, oligonucleotide therapy, and gene editing. At 4BIO Capital, Dima Kuzmin is instrumental in leading investment strategies, identifying pioneering companies, and driving the growth of transformative healthcare solutions.
His role at 4BIO Capital involves overseeing all aspects of the investment lifecycle, from initial deal sourcing and due diligence to portfolio management and strategic exits. Dima's deep understanding of both scientific innovation and financial markets enables him to pinpoint companies with the potential to revolutionize medicine and deliver significant returns. He is particularly keen on early-stage and growth-stage companies that are developing disruptive platforms and therapies addressing critical unmet medical needs across various disease areas.
Before co-founding 4BIO Capital, Dima Kuzmin built a robust career in investment banking, specializing in the healthcare sector. He held significant positions at leading global financial institutions such as UBS and Credit Suisse. During his tenure in investment banking, Dima gained extensive experience in mergers and acquisitions (M&A), capital markets transactions, and strategic advisory for pharmaceutical and biotechnology companies. This background provided him with invaluable insights into the financial intricacies and strategic imperatives of the life sciences industry, which he now leverages to guide 4BIO Capital's investment decisions.
While specific individual investments are often part of 4BIO Capital's broader portfolio, Dima Kuzmin has been central to the firm's strategy of backing companies that are at the forefront of advanced therapy development. These investments typically target firms developing novel therapeutic modalities for rare diseases, oncology, and other areas where conventional treatments fall short. His leadership contributes to 4BIO Capital's reputation for supporting companies that not only promise strong financial returns but also hold the potential for profound patient impact.
Through his work, Dima Kuzmin continues to shape the future of medicine by fostering innovation and providing crucial capital to the next generation of biotech leaders. His blend of scientific acumen and financial expertise makes him a key driver in advancing the field of advanced therapies and bringing life-changing treatments to patients worldwide.
Dima Kuzmin is a Managing Partner at 4BIO Capital, a venture capital firm specializing in advanced therapies. He is a key leader in identifying and investing in innovative biotechnology companies.
Dima Kuzmin, through 4BIO Capital, invests in advanced therapies, including gene therapy, cell therapy, RNA therapy, oligonucleotide therapy, and gene editing. His focus is on early-stage and growth-stage companies developing disruptive solutions for unmet medical needs.
Dima Kuzmin works as a Managing Partner at 4BIO Capital, a specialist venture capital firm dedicated to the advanced therapies sector of biotechnology.
